|
JPS6030654B2
(ja)
*
|
1980-12-31 |
1985-07-17 |
株式会社林原生物化学研究所 |
ヒトコロニ−刺激因子の製造方法
|
|
DE3110611A1
(de)
*
|
1981-03-18 |
1982-10-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen |
"mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
|
|
US4432751A
(en)
*
|
1982-03-05 |
1984-02-21 |
Baylor College Of Medicine |
Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction
|
|
JPS59137417A
(ja)
*
|
1983-01-28 |
1984-08-07 |
Morinaga Milk Ind Co Ltd |
人尿由来コロニ−形成刺激因子及びカリクレインの製造法
|
|
JPS61227526A
(ja)
*
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
UA29377C2
(uk)
*
|
1984-09-19 |
2000-11-15 |
Новартіс Аг |
Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
|
|
US6103224A
(en)
*
|
1985-02-05 |
2000-08-15 |
Chiron Corporation |
N∇2 CSF-1 (short form) and carboxy truncated fragments thereof
|
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US5104650A
(en)
*
|
1985-02-05 |
1992-04-14 |
Cetus Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US6156300A
(en)
*
|
1985-02-05 |
2000-12-05 |
Chiron Corporation |
Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
|
|
US5422105A
(en)
*
|
1985-02-05 |
1995-06-06 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor 1
|
|
WO1986004607A1
(en)
*
|
1985-02-05 |
1986-08-14 |
Cetus Corporation |
Recombinant colony stimulating factor-1
|
|
US4847201A
(en)
*
|
1985-02-05 |
1989-07-11 |
Cetus Corporation |
DNA encoding for CSF-1 and accompanying recombinant systems
|
|
US5792450A
(en)
*
|
1985-02-05 |
1998-08-11 |
Chiron Corporation |
Purified human CSF-1
|
|
US5573930A
(en)
|
1985-02-05 |
1996-11-12 |
Cetus Oncology Corporation |
DNA encoding various forms of colony stimulating factor-1
|
|
JPH0753667B2
(ja)
*
|
1985-08-09 |
1995-06-07 |
新技術開発事業団 |
骨髄移植療法補助剤
|
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
|
US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
|
US4721096A
(en)
*
|
1986-04-18 |
1988-01-26 |
Marrow-Tech Incorporated |
Process for replicating bone marrow in vitro and using the same
|
|
US4963489A
(en)
*
|
1987-04-14 |
1990-10-16 |
Marrow-Tech, Inc. |
Three-dimensional cell and tissue culture system
|
|
US5032508A
(en)
*
|
1988-09-08 |
1991-07-16 |
Marrow-Tech, Inc. |
Three-dimensional cell and tissue culture system
|
|
US5863531A
(en)
*
|
1986-04-18 |
1999-01-26 |
Advanced Tissue Sciences, Inc. |
In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
|
|
US5510254A
(en)
*
|
1986-04-18 |
1996-04-23 |
Advanced Tissue Sciences, Inc. |
Three dimensional cell and tissue culture system
|
|
US5160490A
(en)
*
|
1986-04-18 |
1992-11-03 |
Marrow-Tech Incorporated |
Three-dimensional cell and tissue culture apparatus
|
|
US4871350A
(en)
*
|
1986-11-04 |
1989-10-03 |
Baylor College Of Medicine |
Methods and compositions for preventing secondary cataracts
|
|
US5055291A
(en)
*
|
1986-11-04 |
1991-10-08 |
Baylor College Of Medicine |
Compositions for preventing secondary cataracts
|
|
JPS63245667A
(ja)
*
|
1987-03-31 |
1988-10-12 |
Ube Ind Ltd |
肥満細胞成長活性を有するヒトil−3産生ヒト細胞および肥満細胞成長活性を有するヒトil−3の製造方法
|
|
JP2831012B2
(ja)
*
|
1987-09-22 |
1998-12-02 |
カイロン コーポレイション |
組換えコロニー刺激因子‐1の使用
|
|
US5190876A
(en)
*
|
1988-12-27 |
1993-03-02 |
Emory University |
Method of modifying cellular differentiation and function and compositions therefor
|
|
JPH0747043B2
(ja)
*
|
1990-04-24 |
1995-05-24 |
エイゼンバーグ,マーク |
合成生体皮膚等価物
|
|
US5652337A
(en)
*
|
1991-03-11 |
1997-07-29 |
Creative Biomolecules, Inc. |
OP-3-induced morphogenesis
|
|
CA2104678C
(en)
|
1991-03-11 |
2002-05-14 |
Charles M. Cohen |
Protein-induced morphogenesis
|
|
US6211146B1
(en)
|
1991-03-11 |
2001-04-03 |
Curis, Inc. |
60A protein-induced morphogenesis
|
|
US5460964A
(en)
*
|
1992-04-03 |
1995-10-24 |
Regents Of The University Of Minnesota |
Method for culturing hematopoietic cells
|
|
US5436151A
(en)
*
|
1992-04-03 |
1995-07-25 |
Regents Of The University Of Minnesota |
Method for culturing human hematopoietic stem cells in vitro
|
|
IL110195A
(en)
*
|
1994-07-03 |
2003-10-31 |
David Danon |
Method and system for cultivating macrophages
|
|
US6498142B1
(en)
|
1996-05-06 |
2002-12-24 |
Curis, Inc. |
Morphogen treatment for chronic renal failure
|
|
PT980252E
(pt)
|
1997-05-05 |
2005-01-31 |
Curis Inc |
Terapias para insuficiencia renal aguda
|
|
US8435939B2
(en)
*
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
|
ES2403932T3
(es)
|
2002-08-27 |
2013-05-22 |
Biokine Therapeutics Ltd. |
Antagonista de CXCR4 y uso del mismo
|
|
US8029985B2
(en)
*
|
2004-09-01 |
2011-10-04 |
Vybion, Inc. |
Amplified bioassay
|
|
US8455450B2
(en)
|
2006-12-21 |
2013-06-04 |
Biokine Therapeutics Ltd. |
Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
|
|
WO2010092571A2
(en)
|
2009-02-11 |
2010-08-19 |
Yeda Research And Development Co. Ltd. |
Short beta-defensin-derived peptides
|
|
ES2462517T3
(es)
|
2009-06-14 |
2014-05-23 |
Biokine Therapeutics Ltd. |
Terapia con péptidos para aumentar los niveles de plaquetas
|
|
WO2013160895A1
(en)
|
2012-04-24 |
2013-10-31 |
Biokine Therapeutics Ltd. |
Peptides and use thereof in the treatment of large cell lung cancer
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
BR112018016924A2
(pt)
|
2016-02-23 |
2019-01-02 |
Biolinerx Ltd |
método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
|